Common Contracts

EX-10.1 2 ex10-1.htm OMNIBUS SETTLEMENT AGREEMENT

Settlement Agreement • May 5th, 2020 • California

• Contract Type
  Settlement Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  California

The undersigned, Marina Biotech, Inc., a Delaware corporation (the “Company”), on the one hand, and Vuong Trieu, PhD, an individual resident in California (“VT”), Autotelic Inc., a Delaware corporation (“Autotelic”), Autotelic LLC, a Delaware limited liability company (“Autotelic LLC”), Autotelic BIO (“Autotelic Bio”), Oncotelic, Inc., a Delaware corporation (“Oncotelic”), and LipoMedics, Inc., a Delaware corporation (“Lipomedics”; each of VT, Autotelic, Autotelic LLC, Oncotelic and LipoMedics a “Counterparty” and collectively the “Counterparties”; each of Autotelic, Autotelic LLC, Oncotelic and LipoMedics a “Corporate Counterparty” and collectively the “Corporate Counterparties”; and the Counterparties together with the Company, the “Parties”) on the other hand, have entered into this Omnibus Settlement Agreement (this “Agreement”) as of September 28, 2018.

OMNIBUS SETTLEMENT AGREEMENT

Settlement Agreement • October 3rd, 2018 • Marina Biotech, Inc. • Pharmaceutical preparations • California

• Contract Type
  Settlement Agreement
• Filed
  October 3rd, 2018
• Company
  Marina Biotech, Inc.
• Industry
  Pharmaceutical preparations
• Jurisdiction
  California

The undersigned, Marina Biotech, Inc., a Delaware corporation (the “Company”), on the one hand, and Vuong Trieu, PhD, an individual resident in California (“VT”), Autotelic Inc., a Delaware corporation (“Autotelic”), Autotelic LLC, a Delaware limited liability company (“Autotelic LLC”), Autotelic BIO (“Autotelic Bio”), Oncotelic, Inc., a Delaware corporation (“Oncotelic”), and LipoMedics, Inc., a Delaware corporation (“Lipomedics”; each of VT, Autotelic, Autotelic LLC, Oncotelic and LipoMedics a “Counterparty” and collectively the “Counterparties”; each of Autotelic, Autotelic LLC, Oncotelic and LipoMedics a “Corporate Counterparty” and collectively the “Corporate Counterparties”; and the Counterparties together with the Company, the “Parties”) on the other hand, have entered into this Omnibus Settlement Agreement (this “Agreement”) as of September 28, 2018.